22,500 Bristol Myers Squibb Company $BMY Shares Sold by Axiom Investment Management LLC

Axiom Investment Management LLC trimmed its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 96.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 792 shares of the biopharmaceutical company’s stock after selling 22,500 shares during the quarter. Axiom Investment Management LLC’s holdings in Bristol Myers Squibb were worth $49,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Altura Wealth Advisors Inc. grew its holdings in shares of Bristol Myers Squibb by 1.2% during the third quarter. Altura Wealth Advisors Inc. now owns 13,717 shares of the biopharmaceutical company’s stock valued at $856,000 after buying an additional 161 shares during the last quarter. Capital City Trust Co. FL raised its holdings in Bristol Myers Squibb by 0.7% in the 3rd quarter. Capital City Trust Co. FL now owns 23,321 shares of the biopharmaceutical company’s stock worth $1,455,000 after acquiring an additional 167 shares during the last quarter. Eagle Bay Advisors LLC raised its holdings in Bristol Myers Squibb by 2.6% in the 3rd quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company’s stock worth $408,000 after acquiring an additional 168 shares during the last quarter. Blue Bell Private Wealth Management LLC raised its holdings in Bristol Myers Squibb by 21.1% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 969 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 169 shares during the last quarter. Finally, Boltwood Capital Management lifted its position in Bristol Myers Squibb by 2.5% in the 3rd quarter. Boltwood Capital Management now owns 7,107 shares of the biopharmaceutical company’s stock valued at $443,000 after acquiring an additional 170 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Trading Down 1.5%

Shares of BMY stock opened at $62.20 on Friday. Bristol Myers Squibb Company has a 12-month low of $45.26 and a 12-month high of $68.64. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79. The firm’s 50 day moving average is $62.34 and its 200 day moving average is $60.11. The stock has a market capitalization of $127.15 billion, a P/E ratio of 13.79, a P/E/G ratio of 0.32 and a beta of 0.20.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25. The business had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The firm’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.63 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.45 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb’s payout ratio is presently 55.88%.

Wall Street Analyst Weigh In

BMY has been the topic of several recent analyst reports. UBS Group downgraded Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 5th. Cantor Fitzgerald decreased their price target on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating for the company in a research note on Thursday, October 8th. JPMorgan Chase & Co. upped their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 19th. Finally, The Goldman Sachs Group raised Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and an average price target of $65.46.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Insider Buying and Selling at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Julia A. Haller sold 3,800 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the transaction, the director directly owned 30,279 shares in the company, valued at approximately $1,916,963.49. This represents a 11.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.